Cyclophosphamide for connective tissue disease-associated interstitial lung disease

Area of Science:

• Pulmonology
• Rheumatology
• Immunology

Background:

• Connective tissue disease-associated interstitial lung disease (CTD-ILD) affects approximately one-third of ILD patients, with significant morbidity and mortality, particularly in systemic sclerosis (SSc).
• Cyclophosphamide, a potent immunosuppressant, is used for autoimmune diseases but carries significant toxicities.
• Treatment decisions for CTD-ILD are challenging due to the need to balance potential benefits against severe adverse effects, with limited data on efficacy predictors.

Purpose of the Study:

• To evaluate the efficacy and safety of cyclophosphamide in treating patients with CTD-ILD.
• To compare cyclophosphamide's effects against placebo and mycophenolate in CTD-ILD management.

Main Methods:

• A systematic review and meta-analysis of randomized controlled trials comparing cyclophosphamide with non-cyclophosphamide therapies for at least six months.
• Searches conducted across major databases (CENTRAL, MEDLINE, Embase, CINAHL, Web of Science) up to May 2017.
• Primary outcomes included changes in forced vital capacity (FVC) and diffusing capacity of the lung for carbon monoxide (DLCO), adverse events, and quality of life.

Main Results:

• Four trials with 495 participants (mostly SSc) were analyzed, yielding low-quality evidence.
• Cyclophosphamide showed a significant improvement in FVC compared to placebo (MD 2.83%), but not DLCO. Adverse effects like hematuria and leukopenia increased, leading to higher withdrawal rates.
• No significant difference in lung function was observed when comparing cyclophosphamide to mycophenolate. Increased side effects, including leukopenia and thrombocytopenia, were noted with cyclophosphamide.

Conclusions:

• Cyclophosphamide offers a small benefit in FVC compared to placebo for CTD-ILD, with modest improvement in dyspnea, but not DLCO or compared to mycophenolate.
• Clinicians should consider individual patient factors, anticipate modest FVC benefits, and diligently monitor for adverse effects.
• Further adequately powered studies are needed to investigate cyclophosphamide in specific subgroups (e.g., by HRCT findings, skin involvement in SSc) and compare it with antifibrotic agents.